Xalatan is a drug with an antiglaucoma action.
Release form and composition
Xalatan is produced in the form of a 0.005% eye drop, which is a clear, colorless solution (in 2.5 ml plastic dropper bottles, 1 or 3 bottles in carton packs with first opening control).
The composition of 1 ml drops includes:
- Active ingredient: latanoprost - 50 µg;
- Auxiliary components: benzalkonium chloride, sodium dihydrogen phosphate (monohydrate), sodium hydrogen phosphate (anhydrous), sodium chloride, injection water.
Indications for use
Xalatan is used to reduce elevated intraocular pressure with increased intraocular pressure and open-angle glaucoma.
- Children's age up to 1 year;
- Hypersensitivity to any component of the drug.
Relative (special caution required):
- Pseudophilic, accompanied by rupture of the posterior lens capsule, and aphakia;
- Risk factors that can lead to macular edema, iritis / uveitis;
- Inflammatory and neovascular glaucoma;
- Bronchial asthma;
- Herpetic keratitis in medical history;
- Period before cataract surgery.
It is not recommended to prescribe a drug with active and recurrent herpetic keratitis, especially associated with the use of prostaglandin F 2α analogues.
Adequate strictly controlled studies in pregnant women have not been conducted. During this period, the drug is prescribed only if the intended benefits outweigh the possible risks.
Latanoprost and its metabolites can be excreted in breast milk, so you should use the drug with caution during lactation.
Dosing and Administration
Xalatan is prescribed 1 drop in each affected eye 1 time per day, preferably in the evening.
To reduce the possible systemic effects of latanoprost, immediately after instilling each drop, it is recommended to press on the lower lacrimal point located on the lower eyelid near the inner corner of the eye for 1 minute.
- Skin: eyelid darkening, local skin reactions on the eyelids, rash, toxic epidermal necrolysis;
- Respiratory system: dyspnea, bronchospasm (including exacerbation in patients with a history of bronchial asthma or acute attacks);
- Organ of vision: eye irritation (itching, feeling of sand or a foreign body in the eyes, burning and stinging), blurred vision, dry eye mucosa, conjunctival hyperemia, eye pain, blepharitis, photophobia, transient point erosion of the corneal epithelium, increased iris pigmentation , periorbital edema, conjunctivitis, eyelid edema, keratitis, iritis / uveitis, change in the direction of eyelash growth (which sometimes causes eye irritation), growth of additional lash over meibomian glands, increased pigmentation, increase numbers, thickening and lengthening of eyelashes and vellus hair, erosion and corneal edema, changes in the eyelashes and the periorbital region (leading to a deepening of the upper eyelid sulcus), macular edema (including cystoid);
- Infections: herpetic keratitis;
- Nervous system: dizziness, headache;
- Musculoskeletal system: pains in joints and muscles;
- Other: nonspecific chest pain.
In very rare cases, in patients with significant corneal damage when using phosphate-containing eye drops, its calcification is possible.
There are also cases of retinal detachment and vitreous hemorrhage, retinal embolism in patients with diabetic retinopathy.
Patients who drip the drug in just one eye have a chance of developing heterochromia.
The safety profile of Xalatan in children is similar to that in adults. Compared with adults, nasopharyngitis and fever are more common in children.
The drug should not be used more than 1 time per day, because frequent use leads to a weakening of its action.
In the case of skipping the next dose, it is not necessary to double it, instillation is carried out at the usual time.
If necessary, latanoprost can be used simultaneously with other classes of ophthalmic agents for local use in order to reduce intraocular pressure. However, between instillations should be done in less than 5-minute intervals.
Benzalkonium chloride, which is part of Xalatan, can be absorbed by contact lenses, so before instillation they must be removed and worn no earlier than 15 minutes.
In the case of increased iris pigmentation, the treatment should be continued under close medical supervision, if necessary, the drug should be canceled. Increased pigmentation is usually observed during the first year of treatment, rarely the second and / or third. Over time, the rate of progression of pigmentation decreases and stabilizes after 5 years. In the longer term, the effects of such a reaction have not been studied. After the end of the course of treatment, the enhancement of the brown pigmentation of the iris was not observed, however, the changed eye color may be irreversible.
The described cases of darkening of the eyelid skin, as well as increased pigmentation, thickening, increase in thickness, lengthening and changing the direction of growth of eyelashes are usually reversible and disappear after the abolition of Xalatan.
After instillation, transient blurring of vision is possible, therefore it is necessary to drive vehicles with care and perform activities that require visual acuity and concentration.
Xalatan is incompatible with eye drops, which include thiomersal (precipitation occurs).
With simultaneous instillation with another prostaglandin analog, a paradoxical increase in intraocular pressure is possible, therefore such combinations are contraindicated.
Terms and conditions of storage
Store at a temperature of 2-8 ° C in a dark place with limited access of children.
Shelf life - 3 years.
After opening the bottle, it can be stored at temperatures up to 25 ºС for 4 weeks.